These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 10208431

  • 1. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1.
    Frank RC, Sun X, Berguido FJ, Jakubowiak A, Nimer SD.
    Oncogene; 1999 Mar 04; 18(9):1701-10. PubMed ID: 10208431
    [Abstract] [Full Text] [Related]

  • 2. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
    Elsässer A, Franzen M, Kohlmann A, Weisser M, Schnittger S, Schoch C, Reddy VA, Burel S, Zhang DE, Ueffing M, Tenen DG, Hiddemann W, Behre G.
    Oncogene; 2003 Aug 28; 22(36):5646-57. PubMed ID: 12944913
    [Abstract] [Full Text] [Related]

  • 3. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F, Pisegna S, Diverio D.
    Haematologica; 1997 Aug 28; 82(3):364-70. PubMed ID: 9234595
    [Abstract] [Full Text] [Related]

  • 4. Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies.
    Kurokawa M, Tanaka T, Tanaka K, Ogawa S, Mitani K, Yazaki Y, Hirai H.
    Oncogene; 1996 Feb 15; 12(4):883-92. PubMed ID: 8632911
    [Abstract] [Full Text] [Related]

  • 5. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B.
    Frank R, Zhang J, Uchida H, Meyers S, Hiebert SW, Nimer SD.
    Oncogene; 1995 Dec 21; 11(12):2667-74. PubMed ID: 8545124
    [Abstract] [Full Text] [Related]

  • 6. The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence.
    Kurokawa M, Ogawa S, Tanaka T, Mitani K, Yazaki Y, Witte ON, Hirai H.
    Oncogene; 1995 Sep 07; 11(5):833-40. PubMed ID: 7675444
    [Abstract] [Full Text] [Related]

  • 7. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
    Fliegauf M, Stock M, Berg T, Lübbert M.
    Oncogene; 2004 Dec 02; 23(56):9070-81. PubMed ID: 15489901
    [Abstract] [Full Text] [Related]

  • 8. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia.
    Meyers S, Lenny N, Sun W, Hiebert SW.
    Oncogene; 1996 Jul 18; 13(2):303-12. PubMed ID: 8710369
    [Abstract] [Full Text] [Related]

  • 9. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene.
    Yergeau DA, Hetherington CJ, Wang Q, Zhang P, Sharpe AH, Binder M, Marín-Padilla M, Tenen DG, Speck NA, Zhang DE.
    Nat Genet; 1997 Mar 18; 15(3):303-6. PubMed ID: 9054947
    [Abstract] [Full Text] [Related]

  • 10. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.
    Linggi B, Müller-Tidow C, van de Locht L, Hu M, Nip J, Serve H, Berdel WE, van der Reijden B, Quelle DE, Rowley JD, Cleveland J, Jansen JH, Pandolfi PP, Hiebert SW.
    Nat Med; 2002 Jul 18; 8(7):743-50. PubMed ID: 12091906
    [Abstract] [Full Text] [Related]

  • 11. Leukemogenic AML1-ETO fusion protein increases carcinogen-DNA adduct formation with upregulated expression of cytochrome P450-1A1 gene.
    Xu M, Li D, Lu Y, Chen GQ.
    Exp Hematol; 2007 Aug 18; 35(8):1249-55. PubMed ID: 17560011
    [Abstract] [Full Text] [Related]

  • 12. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
    Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G, Hiddemann W, Zhang DE, Tenen DG.
    Nat Med; 2001 Apr 18; 7(4):444-51. PubMed ID: 11283671
    [Abstract] [Full Text] [Related]

  • 13. Transformation properties of the ETO gene, fusion partner in t(8:21) leukemias.
    Wang J, Wang M, Liu JM.
    Cancer Res; 1997 Jul 15; 57(14):2951-5. PubMed ID: 9230207
    [Abstract] [Full Text] [Related]

  • 14. B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos.
    Echlin DR, Tae HJ, Mitin N, Taparowsky EJ.
    Oncogene; 2000 Mar 30; 19(14):1752-63. PubMed ID: 10777209
    [Abstract] [Full Text] [Related]

  • 15. The AML1/ETO fusion protein activates transcription of BCL-2.
    Klampfer L, Zhang J, Zelenetz AO, Uchida H, Nimer SD.
    Proc Natl Acad Sci U S A; 1996 Nov 26; 93(24):14059-64. PubMed ID: 8943060
    [Abstract] [Full Text] [Related]

  • 16. Discrimination of target by siRNA: designing of AML1-MTG8 fusion mRNA-specific siRNA sequences.
    Kasashima K, Sakota E, Kozu T.
    Biochimie; 2004 Nov 26; 86(9-10):713-21. PubMed ID: 15556282
    [Abstract] [Full Text] [Related]

  • 17. Functional domains of the t(8;21) fusion protein, AML-1/ETO.
    Lenny N, Meyers S, Hiebert SW.
    Oncogene; 1995 Nov 02; 11(9):1761-9. PubMed ID: 7478604
    [Abstract] [Full Text] [Related]

  • 18. Molecular mechanisms of leukemogenesis by AML1/EVI-1.
    Mitani K.
    Oncogene; 2004 May 24; 23(24):4263-9. PubMed ID: 15156182
    [Abstract] [Full Text] [Related]

  • 19. The ETO portion of acute myeloid leukemia t(8;21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor.
    Erickson PF, Robinson M, Owens G, Drabkin HA.
    Cancer Res; 1994 Apr 01; 54(7):1782-6. PubMed ID: 8137293
    [Abstract] [Full Text] [Related]

  • 20. Block of granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed Bcl-2.
    Kohzaki H, Ito K, Huang G, Wee HJ, Murakami Y, Ito Y.
    Oncogene; 1999 Jul 15; 18(28):4055-62. PubMed ID: 10435586
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.